- Home
- LTRX vs ZNTL Comparison
LTRX vs ZNTL Comparison
Compare LTRX & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LTRX
- ZNTL
- Stock Information
- Founded
- LTRX 1989
- ZNTL 2014
- Country
- LTRX United States
- ZNTL United States
- Employees
- LTRX N/A
- ZNTL N/A
- Industry
- LTRX Computer Communications Equipment
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- LTRX Telecommunications
- ZNTL Health Care
- Exchange
- LTRX Nasdaq
- ZNTL Nasdaq
- Market Cap
- LTRX 106.5M
- ZNTL 102.2M
- IPO Year
- LTRX 2000
- ZNTL 2020
- Fundamental
- Price
- LTRX $2.15
- ZNTL $1.28
- Analyst Decision
- LTRX Strong Buy
- ZNTL Buy
- Analyst Count
- LTRX 5
- ZNTL 9
- Target Price
- LTRX $5.10
- ZNTL $8.69
- AVG Volume (30 Days)
- LTRX 252.4K
- ZNTL 687.2K
- Earning Date
- LTRX 05-08-2025
- ZNTL 05-14-2025
- Dividend Yield
- LTRX N/A
- ZNTL N/A
- EPS Growth
- LTRX N/A
- ZNTL N/A
- EPS
- LTRX N/A
- ZNTL N/A
- Revenue
- LTRX $143,159,000.00
- ZNTL $26,865,000.00
- Revenue This Year
- LTRX N/A
- ZNTL N/A
- Revenue Next Year
- LTRX $3.20
- ZNTL N/A
- P/E Ratio
- LTRX N/A
- ZNTL N/A
- Revenue Growth
- LTRX N/A
- ZNTL N/A
- 52 Week Low
- LTRX $1.91
- ZNTL $1.01
- 52 Week High
- LTRX $4.55
- ZNTL $12.68
- Technical
- Relative Strength Index (RSI)
- LTRX 44.90
- ZNTL 48.95
- Support Level
- LTRX $2.13
- ZNTL $1.18
- Resistance Level
- LTRX $2.31
- ZNTL $1.27
- Average True Range (ATR)
- LTRX 0.11
- ZNTL 0.07
- MACD
- LTRX -0.00
- ZNTL 0.01
- Stochastic Oscillator
- LTRX 35.94
- ZNTL 80.00
About LTRX Lantronix Inc.
Lantronix Inc is a networking company. It provides secure data access and management solutions for the Internet of Things (IoT) and information technology assets. It organizes its products and solutions into three product lines: Embedded IoT Solutions, IoT Systems Solutions, and Software and Services. The IoT System Solutions segment is the key revenue driver for the company. The company serves a diverse range of markets including healthcare, industrial, security, energy, transportation, and government networking. Its primary geographic markets are the Americas, Europe, the Middle East and Africa, and Asia Pacific Japan. The Americas contribute the vast majority of total revenue.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.